144 related articles for article (PubMed ID: 20003187)
1. The effect on the small bowel of 5-FU and oxaliplatin in combination with radiation using a microcolony survival assay.
Gunnlaugsson A; Nilsson P; Kjellén E; Johnsson A
Radiat Oncol; 2009 Dec; 4():61. PubMed ID: 20003187
[TBL] [Abstract][Full Text] [Related]
2. Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer.
Gunnlaugsson A; Kjellén E; Nilsson P; Bendahl PO; Willner J; Johnsson A
Acta Oncol; 2007; 46(7):937-44. PubMed ID: 17851844
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
Rosenthal DI; Catalano PJ; Haller DG; Landry JC; Sigurdson ER; Spitz FR; Benson AB
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):108-13. PubMed ID: 18722265
[TBL] [Abstract][Full Text] [Related]
5. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
[TBL] [Abstract][Full Text] [Related]
6. Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.
Wolff HA; Conradi LC; Schirmer M; Beissbarth T; Sprenger T; Rave-Fränk M; Hennies S; Hess CF; Becker H; Christiansen H; Liersch T
Oncologist; 2011; 16(5):621-31. PubMed ID: 21558132
[TBL] [Abstract][Full Text] [Related]
7. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
Ordu AD; Nieder C; Geinitz H; Scherer V; Kup PG; Schuster T; Combs SE; Fakhrian K
Anticancer Res; 2014 Dec; 34(12):7255-61. PubMed ID: 25503157
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck.
Budach W; Hehr T; Budach V; Belka C; Dietz K
BMC Cancer; 2006 Jan; 6():28. PubMed ID: 16448551
[TBL] [Abstract][Full Text] [Related]
9. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
11. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
Movsas B; Hanlon AL; Lanciano R; Scher RM; Weiner LM; Sigurdson ER; Hoffman JP; Eisenberg BL; Cooper HS; Provins S; Coia LR
Int J Radiat Oncol Biol Phys; 1998 Aug; 42(1):43-50. PubMed ID: 9747818
[TBL] [Abstract][Full Text] [Related]
13. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
[TBL] [Abstract][Full Text] [Related]
14. Microcolony survival assay for jejunal crypt cells exposed to radiation alone and combined with cancer chemotherapeutic agents--methodological problems.
von der Maase H; Overgaard J
Int J Radiat Biol Relat Stud Phys Chem Med; 1983 Jan; 43(1):45-56. PubMed ID: 6339433
[TBL] [Abstract][Full Text] [Related]
15. Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial.
Freyer G; Bossard N; Romestaing P; Mornex F; Chapet O; Trillet-Lenoir V; Gérard JP
J Clin Oncol; 2001 May; 19(9):2433-8. PubMed ID: 11331322
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor.
Khan WB; Shui C; Ning S; Knox SJ
Radiat Res; 1997 Sep; 148(3):248-53. PubMed ID: 9291356
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Dipetrillo T; Pricolo V; Lagares-Garcia J; Vrees M; Klipfel A; Cataldo T; Sikov W; McNulty B; Shipley J; Anderson E; Khurshid H; Oconnor B; Oldenburg NB; Radie-Keane K; Husain S; Safran H
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):124-9. PubMed ID: 20947267
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Rödel C; Liersch T; Becker H; Fietkau R; Hohenberger W; Hothorn T; Graeven U; Arnold D; Lang-Welzenbach M; Raab HR; Sülberg H; Wittekind C; Potapov S; Staib L; Hess C; Weigang-Köhler K; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R;
Lancet Oncol; 2012 Jul; 13(7):679-87. PubMed ID: 22627104
[TBL] [Abstract][Full Text] [Related]
19. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Aschele C; Cionini L; Lonardi S; Pinto C; Cordio S; Rosati G; Artale S; Tagliagambe A; Ambrosini G; Rosetti P; Bonetti A; Negru ME; Tronconi MC; Luppi G; Silvano G; Corsi DC; Bochicchio AM; Chiaulon G; Gallo M; Boni L
J Clin Oncol; 2011 Jul; 29(20):2773-80. PubMed ID: 21606427
[TBL] [Abstract][Full Text] [Related]
20. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
